ClinicalTrials.gg
CompletedNCT03104400SELECT - PsA 1Updated Sep 22, 2025Results posted

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

A Phase 3 interventional study of Adalimumab and Upadacitinib in Psoriatic Arthritis, sponsored by AbbVie. Completed at 345 sites in 46 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,705
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
Largest of 11
1,705 · median 246
Started
2017
with 2 others
Phase 3
5 of 34
1 open now
Registered
21st of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 21st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg and 30 mg QD versus placebo for the prevention of structural progression.

The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg and 30 mg QD in participants who have completed Period 1.

Read the detailed description

The study includes a 35-day screening period, a 56-week blinded period (Period 1), a long-term extension period of up to a total treatment duration of approximately 5 years (Period 2), a 30-day follow-up call or visit, and a 70-day follow-up call.

Period 1 includes 24 weeks of randomized, double-blind, placebo-controlled and active comparator-controlled treatment followed by 32 weeks of active comparator-controlled upadacitinib; at Week 24 participants assigned to placebo will be switched to upadacitinib according to their randomization assignment.

Participants who meet eligibility criteria will be randomized in a 2:2:2:1:1 ratio to one of five treatment groups:

  • Group 1: Upadacitinib 15 mg QD
  • Group 2: Upadacitinib 30 mg QD
  • Group 3: Adalimumab 40 mg every other week (EOW)
  • Group 4: Placebo followed by upadacitinib 15 mg QD
  • Group 5: Placebo followed by upadacitinib 30 mg QD

Randomization will be stratified by extent of psoriasis (≥ 3% body surface area [BSA] or \< 3% BSA), current use of at least 1 non-biologic DMARD, presence of dactylitis, and presence of enthesitis, except for participants from China and Japan, where randomization for each country will be stratified by extent of psoriasis (≥ 3% BSA or \< 3% BSA) only.

Participants who complete the Week 56 visit (end of Period 1) will enter the long-term extension portion of the study, Period 2 (total treatment up to approximately 5 years), and continue study treatment as assigned in Period 1 in a blinded manner until the last subject completes the last visit of Period 1 (Week 56), when study drug assignment in both periods will be unblinded and participants will be dispensed study drug in an open-label fashion until the completion of Period 2.

At Week 16, rescue therapy will be offered to participants classified as non-responders (defined as not achieving at least 20% improvement in tender joint count (TJC) and / or swollen joint count (SJC) at both Week 12 and Week 16). Starting at Week 36, participants who fail to demonstrate at least 20% improvement in either or both TJC and SJC compared to Baseline at 2 consecutive visits will be discontinued from study drug treatment. Additionally, in participants continuing on study drug, starting at the Week 36 visit, initiation of or change in background PsA medication(s) is allowed as per local label.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Arthritis
  • Psoriasis
  • Anti-inflammatory
  • Joint disease
  • Musculoskeletal disease
  • Anti-Rheumatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) criteria.
  • Participant has active disease at Baseline defined as >= 3 tender joints (based on 68 joint counts) and >= 3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.
  • Presence of either at Screening:

    1. >= 1 erosion on x-ray as determined by central imaging review or;
    2. high-sensitivity C-reactive protein (hs-CRP) > laboratory defined (ULN).
  • Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.
  • Participant has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) to previous or current treatment with at least 1 non-biologic DMARD at maximally tolerated dose (methotrexate (MTX), sulfasalazine (SSZ), leflunomide (LEF), cyclosporine, apremilast, bucillamin or iguratimod), or participant has an intolerance to or for DMARDs as defined by the investigator.
  • Participant who is on current treatment with concomitant non-biologic DMARDs at study entry must be on \<= 2 non-biologic DMARDs (except the combination of MTX and leflunomide). The following non-biologic DMARDs are allowed: MTX, sulfasalazine, leflunomide, apremilast, hydroxychloroquine (HCQ) , bucillamine or iguratimod, and have been ongoing for >= 12 weeks and at stable dose for >= 4 weeks prior to the Baseline Visit. No other DMARDs are permitted during the study.

    i. Participants who need to discontinue DMARDs prior to the Baseline Visit to comply with this inclusion criterion must follow the procedure specified below or at least five times the mean terminal elimination half-life of a drug:

    1. >= 8 weeks for LEF if no elimination procedure was followed, or adhere to an elimination procedure (i.e., 11 days with cholestyramine, or 30 days washout with activated charcoal or as per local label);
    2. >= 4 weeks for all others.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus Kinase (JAK) inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, and filgotinib).
  • Current treatment with > 2 non-biologic DMARDs; or use of DMARDs other than methotrexate, sulfasalazine, leflunomide, apremilast, hydroxychloroquine, bucillamine, or iguratimod; or use of methotrexate in combination with leflunomide.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than PsA (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). Prior history of reactive arthritis or axial spondyloarthritis including ankylosing spondylitis and nonradiographic axial spondyloarthritis is permitted if documentation of change in diagnosis to PsA or additional diagnosis of PsA is made. Prior history of fibromyalgia is permitted if documentation of change in diagnosis to PsA or documentation that the diagnosis of fibromyalgia was made incorrectly.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,705 participants (actual)

Study arms

  • Experimental
    Upadacitinib 15 mg

    Period 1: Participants receive upadacitinib 15 mg orally once a day (QD) and matching placebo to adalimumab by subcutaneous injection every other week (EOW) for 56 weeks. Period 2: Participants will continue to receive upadacitinib 15 mg once daily.

    Drug: Upadacitinib · Drug: Placebo to Adalimumab

  • Experimental
    Upadacitinib 30 mg

    Period 1: Participants receive upadacitinib 30 mg orally once a day and matching placebo to adalimumab by subcutaneous injection every other week for 56 weeks. Period 2: Participants will continue to receive upadacitinib 30 mg once daily.

    Drug: Upadacitinib · Drug: Placebo to Adalimumab

  • Active comparator
    Adalimumab

    Period 1: Participants receive adalimumab 40 mg by subcutaneous injection every other week and matching placebo to upadacitinib orally QD for 56 weeks. Period 2: Participants continue to receive adalimumab 40 mg every other week.

    Drug: Adalimumab · Drug: Placebo to Upadacitinib

  • Placebo comparator
    Placebo / Upadacitinib 15 mg

    Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 15 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks. Period 2: Participants will continue to receive upadacitinib 15 mg once daily.

    Drug: Upadacitinib · Drug: Placebo to Upadacitinib · Drug: Placebo to Adalimumab

  • Placebo comparator
    Placebo / Upadacitinib 30 mg

    Period 1: Participants receive matching placebo to upadacitinib orally once a day for 24 weeks then upadacitinib 30 mg once daily for 32 weeks, and matching placebo to adalimumab by subcutaneous injection EOW for the entire 56 weeks. Period 2: Participants will continue to receive upadacitinib 30 mg once daily.

    Drug: Upadacitinib · Drug: Placebo to Upadacitinib · Drug: Placebo to Adalimumab

Interventions

  • Administered by subcutaneous injection

    Also known as: Humira®

  • Oral tablet

    Also known as: ABT 494, RINVOQ®

  • DrugPlacebo to Upadacitinib

    Oral tablet

  • DrugPlacebo to Adalimumab

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16

    The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).

    Time frame: Baseline and Week 16

  3. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16

    PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

    Time frame: Baseline and Week 16

  4. Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24

    The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst). A negative change from Baseline indicates improvement in joint damage.

    Time frame: Baseline and Week 24

  5. Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

    A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)

    Time frame: Week 24

  6. Percentage of Participants With Resolution of Enthesitis at Week 24

    Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).

    Time frame: Week 24

  7. Percentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  8. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  9. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  10. Percentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  11. Percentage of Participants With Resolution of Dactylitis at Week 24

    Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The Leeds Dactylitis Index (LDI) is a score based on finger circumference and tenderness, assessed and summed across all dactylitic digits (fingers and toes). The presence of a dactylitic digit is defined as at least one affected AND tender digit with circumference increase over reference digit ≥ 10%. The reference digit circumference is either the contralateral digit (unaffected digit on opposite hand or foot) if available, or from a standard reference table if otherwise. Tenderness of affected digits is assessed on a scale from 0 \[none\] to 3 \[worst\]. The ratio of circumference between an affected digit and reference digit is multiplied by the tenderness score for each affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.

    Time frame: Week 24

  12. Change From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab

    Participants were asked to indicate the severity of their arthritis pain within the previous week on a numerical rating scale (NRS) from 0 to 10. A score of 0 indicates "no pain" and a score of 10 indicates "worst possible pain." A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  13. Change From Baseline in HAQ-DI - Superiority Versus Adalimumab

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  14. Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16

    The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.

    Time frame: Baseline and Week 16

  15. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  16. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  17. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 2

07

Results

Posted Jan 25, 2022

Participant flow

This study was conducted at 282 sites in 44 countries and was initiated in April 2017. Adults with active psoriatic arthritis (PsA) and a history of inadequate response or intolerance to at least one non-biologic disease modifying anti-rheumatic drug (DMARD) were eligible for enrollment.

Period 1 (Week 1 - 56)
Participant flow — Period 1 (Week 1 - 56)
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgPlacebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Adalimumab 40 mg Period 2 (Weeks 56 to 260)Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg Period 2 (Weeks 56 to 260)
Started21121242943042300000
Completed17717837037936600000
Not completed343459515700000
Withdrew: Adverse event571192100000
Withdrew: Withdrawal by subject172029242400000
Withdrew: Lost to follow-up4148700000
Withdrew: Lack of efficacy6382100000
Withdrew: Covid-19 logistical restrictions0001000000
Withdrew: Other, not specified2376400000
Withdrew: Did not receive study drug0001000000
Period 2 Week 56 - 260)
Participant flow — Period 2 Week 56 - 260)
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgPlacebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Adalimumab 40 mg Period 2 (Weeks 56 to 260)Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg Period 2 (Weeks 56 to 260)
Started00000177178366378365
Completed00000131121268272269
Not completed0000046579810696
Withdrew: Adverse event000001417142828
Withdrew: Withdrawal by subject000001121454432
Withdrew: Lost to follow-up000007612127
Withdrew: Lack of efficacy0000044967
Withdrew: Coviid-19 infection0000002023
Withdrew: Covid-19 logistical restrictions0000000110
Withdrew: Other, not specified00000107171218
Withdrew: Other0000000011

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1236.2 (31.6 to 40.7)65.0 (60.5 to 69.5)70.6 (66.3 to 74.9)78.5 (74.6 to 82.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 34.5 · 95% CI 28.2 to 40.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 42.3 · 95% CI 36.3 to 48.3Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
units on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.14 (-0.18 to -0.09)-0.34 (-0.38 to -0.29)-0.42 (-0.47 to -0.37)-0.47 (-0.52 to -0.42)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Least squares (ls) mean difference: -0.28 · 95% CI -0.35 to -0.22Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -0.34 · 95% CI -0.40 to -0.27Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16

The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 1610.9 (7.4 to 14.3)38.5 (33.2 to 43.7)41.9 (36.5 to 47.3)54.0 (48.6 to 59.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 31.1 · 95% CI 24.7 to 37.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 43.1 · 95% CI 36.7 to 49.6Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 1621.3 (15.8 to 26.9)53.1 (46.3 to 59.8)62.6 (56.1 to 69.1)62.4 (55.8 to 68.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 41.3 · 95% CI 32.8 to 49.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 41.1 · 95% CI 32.5 to 49.6Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24

The Sharp-van der Heijde modified scoring method for PsA measures the level of joint damage from radiographs of the hands and feet, and was assessed by 2 independent, blinded readers. Joint erosion severity was assessed in 20 joints in each hand and wrist and 6 joints in each foot. Each joint was scored from 0 (no erosion) to 5 for hands/wrists or to 10 for feet (complete collapse). The total erosion score ranges from 0 to 320 (worst). Joint space narrowing (JSN) was assessed in 20 joints of each hand and wrist, and 6 joints of each foot, from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation). The total JSN score ranges from 0 to 208 (worst). Joints with gross osteolysis or pencil in cup were assigned the maximum score for both erosions and JSN. The total mTSS score is the sum of the joint erosion and JSN scores and ranges from 0 (normal) to 528 (worst). A negative change from Baseline indicates improvement in joint damage.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 24
score on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Modified PsA Total Sharp/Van Der Heijde Score (mTSS) at Week 240.25 (0.13 to 0.36)0.01 (-0.11 to 0.13)-0.04 (-0.16 to 0.07)0.03 (-0.08 to 0.15)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = 0.0002 · Ls mean difference: -0.29 · 95% CI -0.44 to -0.14Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = 0.0069 · Ls mean difference: -0.21 · 95% CI -0.36 to -0.06Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 2412.3 (9.2 to 15.4)33.3 (28.9 to 37.8)36.6 (32.0 to 41.2)45.4 (40.6 to 50.1)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel (CMH) test adjusted for the main stratification factor of current DMARD use (yes/no).) · Response rate difference: 24.3 · 95% CI 18.8 to 29.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 33.1 · 95% CI 27.4 to 38.8Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With Resolution of Enthesitis at Week 24

Resolution of enthesitis is defined as a Leeds Enthesitis Index (LEI) score = 0. LEI is an enthesitis measure developed specifically for PsA and assesses the presence or absence of tenderness at the following 3 bilateral enthesial sites: medial femoral condyles, lateral epicondyles of the humerus, and Achilles tendon insertions. Tenderness on examination is recorded as either present (coded as 1), absent (coded as 0), or not assessed for each of the 6 sites. The LEI is calculated by taking the sum of the scores from the 6 sites. The LEI ranges from 0 to 6 (worst).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Enthesitis at Week 24
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With Resolution of Enthesitis at Week 2432.4 (26.5 to 38.3)47.2 (41.2 to 53.2)53.7 (47.8 to 59.7)57.7 (51.8 to 63.6)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 21.3 · 95% CI 13.0 to 29.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 25.3 · 95% CI 16.9 to 33.7Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an ACR20 Response at Week 12 - Non-inferiority Versus Adalimumab36.2 (31.6 to 40.7)65.0 (60.5 to 69.5)70.6 (66.3 to 74.9)78.5 (74.6 to 82.4)
Statistical analysis
  • Adalimumab 40 mg vs Upadacitinib 15 mg · Koch 3-Arm Test · p = <0.0001 · Percent adalimumab effect preservation: 119.381 · 95% CI 97.987 to 147.942The percent of adalimumab effect preservation is the point estimate of 3-arm non-inferiority analysis, which is calculated by (Upadacitinib - Placebo) / (Adalimumab - Placebo) \* 100.
  • Adalimumab 40 mg vs Upadacitinib 30 mg · Koch 3-Arm Test · p = <0.0001 · Percent adalimumab effect preservation: 146.604 · 95% CI 122.817 to 180.398The percent of adalimumab effect preservation is the point estimate of 3-arm non-inferiority analysis, which is calculated by (Upadacitinib - Placebo) / (Adalimumab - Placebo) \* 100.
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
score on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 123.19 (2.41 to 3.96)6.82 (6.07 to 7.58)7.86 (7.09 to 8.63)8.90 (8.13 to 9.68)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 4.67 · 95% CI 3.67 to 5.67Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 5.72 · 95% CI 4.71 to 6.72Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
score on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 122.8 (1.9 to 3.7)5.7 (4.8 to 6.6)6.3 (5.4 to 7.2)7.1 (6.2 to 8.0)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 3.5 · 95% CI 2.4 to 4.7Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 4.3 · 95% CI 3.1 to 5.5Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an ACR20 Response at Week 12 - Superiority Versus Adalimumab36.2 (31.6 to 40.7)65.0 (60.5 to 69.5)70.6 (66.3 to 74.9)78.5 (74.6 to 82.4)
Statistical analysis
  • Adalimumab 40 mg vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.0815 · Response rate difference: 5.6 · 95% CI -0.6 to 11.8Response Rate Difference = Upadacitinib - Adalimumab
  • Adalimumab 40 mg vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Ls mean difference: 13.5 · 95% CI 7.5 to 19.4Response Rate Difference = Upadacitinib - Adalimumab
SecondaryPercentage of Participants With Resolution of Dactylitis at Week 24

Resolution of dactylitis is defined as a Leeds Dactylitis Index (LDI) score = 0. The Leeds Dactylitis Index (LDI) is a score based on finger circumference and tenderness, assessed and summed across all dactylitic digits (fingers and toes). The presence of a dactylitic digit is defined as at least one affected AND tender digit with circumference increase over reference digit ≥ 10%. The reference digit circumference is either the contralateral digit (unaffected digit on opposite hand or foot) if available, or from a standard reference table if otherwise. Tenderness of affected digits is assessed on a scale from 0 \[none\] to 3 \[worst\]. The ratio of circumference between an affected digit and reference digit is multiplied by the tenderness score for each affected digit. The results from each involved digit are summed to provide the final LDI. A higher LDI indicates worse dactylitis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Resolution of Dactylitis at Week 24
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With Resolution of Dactylitis at Week 2439.7 (31.1 to 48.2)74.0 (66.4 to 81.6)76.5 (69.3 to 83.6)79.5 (72.5 to 86.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Response rate difference: 36.8 · 95% CI 25.7 to 47.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Response rate difference: 39.8 · 95% CI 28.8 to 50.9Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab

Participants were asked to indicate the severity of their arthritis pain within the previous week on a numerical rating scale (NRS) from 0 to 10. A score of 0 indicates "no pain" and a score of 10 indicates "worst possible pain." A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab
units on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Patient's Assessment of Pain - Superiority Versus Adalimumab-0.9 (-1.2 to -0.7)-2.3 (-2.5 to -2.1)-2.3 (-2.5 to -2.0)-2.7 (-2.9 to -2.5)
Statistical analysis
  • Adalimumab 40 mg vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = 0.8970 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: 0.0 · 95% CI -0.3 to 0.3Treatment Difference = Upadacitinib - Adalimumab
  • Adalimumab 40 mg vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = 0.0028 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2Treatment Difference = Upadacitinib - Adalimumab
SecondaryChange From Baseline in HAQ-DI - Superiority Versus Adalimumab

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAQ-DI - Superiority Versus Adalimumab
score on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in HAQ-DI - Superiority Versus Adalimumab-0.14 (-0.18 to -0.09)-0.34 (-0.38 to -0.29)-0.42 (-0.47 to -0.37)-0.47 (-0.52 to -0.42)
Statistical analysis
  • Adalimumab 40 mg vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = 0.0162 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: -0.08 · 95% CI -0.15 to -0.01Treatment Difference = Upadacitinib - Adalimumab
  • Adalimumab 40 mg vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: -0.14 · 95% CI -0.20 to -0.07Treatment Difference = Upadacitinib - Adalimumab
SecondaryChange From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16

The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16
score on a scalePlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16-8.2 (-10.2 to -6.3)-22.7 (-24.7 to -20.8)-25.3 (-27.3 to -23.4)-28.1 (-30.0 to -26.1)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: -17.1 · 95% CI -19.6 to -14.6Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 (This comparison was not tested for statistical significance because the hierarchical testing procedures stopped at ACR 20 at Week 12 superiority test of upadacitinib 15 mg versus adalimumab 40 mg.) · Ls mean difference: -19.8 · 95% CI -22.3 to -17.3Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1213.2 (10.0 to 16.5)37.5 (32.9 to 42.1)37.5 (32.9 to 42.1)51.8 (47.0 to 56.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 24.3 · 95% CI 18.7 to 29.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 38.5 · 95% CI 32.8 to 44.3Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 122.4 (0.9 to 3.8)13.8 (10.5 to 17.0)15.6 (12.2 to 19.1)25.3 (21.2 to 29.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 13.3 · 95% CI 9.5 to 17.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 22.9 · 95% CI 18.5 to 27.3Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2
percentage of participantsPlaceboAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 212.1 (9.0 to 15.2)30.3 (26.0 to 34.7)28.2 (23.9 to 32.5)38.3 (33.7 to 42.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 16.1 · 95% CI 10.9 to 21.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (This comparison was not part of the pre-specified multiplicity testing sequence.) · Response rate difference: 26.2 · 95% CI 20.7 to 31.8Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed to end of the study. Median time on follow-up in Period 1 (days): Upa 15 mg (415); Upa 30 mg (414); Ada 40 mg (194); Pbo up to Wk 24 (418); Pbo/Upa 15 mg Wk 24-56 (419); and Pbo/Upa 30 mg Wk 24-56 (776.5). Median time on follow-up in Period 2 (days): Upa 15 mg (1458); Upa 30 mg (796.5); Ada 40 mg (1486); Pbo/Upa 15 mg (1459); Pbo/Upa 30 mg (790.5); and Upa 30 mg/Upa 15 mg (842).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Upadacitinib 15 mg Period 1 (Weeks 1 to 56)3/430 (0.7%)28/430 (6.5%)247/430 (57.4%)
Upadacitinib 30 mg Period 1 (Weeks 1 to 56)1/423 (0.2%)46/423 (10.9%)262/423 (61.9%)
Adalimumab 40 mg Period 1 (Weeks 1 to 56)1/429 (0.2%)35/429 (8.2%)220/429 (51.3%)
Placebo Period 1 (Weeks 1 to 24)1/423 (0.2%)13/423 (3.1%)150/423 (35.5%)
Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56)0/188 (0%)10/188 (5.3%)61/188 (32.4%)
Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56)0/190 (0%)11/190 (5.8%)76/190 (40%)
Upadacitinib 15 mg Period 2 (Weeks 56 to 260)14/378 (3.7%)109/378 (28.8%)277/378 (73.3%)
Upadacitinib 30 mg Period 2 (Weeks 56 to 260)8/366 (2.2%)66/366 (18%)218/366 (59.6%)
Adalimumab 40 mg Period 2 (Weeks 56 to 260)4/366 (1.1%)73/366 (19.9%)246/366 (67.2%)
Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)3/177 (1.7%)34/177 (19.2%)130/177 (73.4%)
Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)3/178 (1.7%)25/178 (14%)114/178 (64%)
Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)6/443 (1.4%)55/443 (12.4%)271/443 (61.2%)
Most frequent serious events
Showing 10 of 332
Most frequent serious events
EventUpadacitinib 15 mg Period 1 (Weeks 1 to 56)Upadacitinib 30 mg Period 1 (Weeks 1 to 56)Adalimumab 40 mg Period 1 (Weeks 1 to 56)Placebo Period 1 (Weeks 1 to 24)Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56)Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56)Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Adalimumab 40 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)
COVID-19 PNEUMONIAInfections and infestations0/4300/4230/4290/4230/1880/19018/37816/3663/3668/1776/1785/443
COVID-19Infections and infestations0/4300/4230/4290/4230/1880/1908/3788/3664/3661/1771/1784/443
PNEUMONIAInfections and infestations2/4304/4231/4292/4230/1881/1907/3782/3661/3661/1771/1780/443
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/4302/4233/4290/4230/1881/1905/3783/3665/3661/1771/1785/443
SUDDEN DEATHGeneral disorders0/4300/4230/4290/4230/1880/1902/3780/3660/3662/1770/1780/443
HERPES ZOSTERInfections and infestations1/4301/4230/4290/4230/1881/1901/3784/3660/3660/1770/1780/443
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/4301/4230/4290/4230/1880/1903/3784/3661/3660/1771/1780/443
ATRIAL FIBRILLATIONCardiac disorders0/4300/4231/4290/4230/1880/1904/3781/3663/3660/1770/1780/443
FOOT DEFORMITYMusculoskeletal and connective tissue disorders0/4300/4230/4290/4230/1880/1901/3780/3663/3660/1770/1781/443
MYOCARDIAL INFARCTIONCardiac disorders1/4302/4230/4290/4230/1880/1903/3781/3661/3660/1770/1780/443
Most frequent other events
Showing 10 of 24
Most frequent other events
EventUpadacitinib 15 mg Period 1 (Weeks 1 to 56)Upadacitinib 30 mg Period 1 (Weeks 1 to 56)Adalimumab 40 mg Period 1 (Weeks 1 to 56)Placebo Period 1 (Weeks 1 to 24)Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56)Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56)Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Adalimumab 40 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260)Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260)
COVID-19Infections and infestations0/4300/4230/4290/4231/1881/190132/37851/366106/36657/17729/178117/443
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations67/43072/42353/42934/42313/18811/19056/37840/36642/36625/17715/17849/443
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations52/43067/42331/4296/42311/18815/19043/37833/36621/36622/17725/17839/443
PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders14/43021/42320/42913/4232/1885/19042/37820/36633/36615/17710/17833/443
URINARY TRACT INFECTIONInfections and infestations26/43030/42318/42910/4234/1889/19041/37821/36626/36615/17712/17825/443
NASOPHARYNGITISInfections and infestations36/43045/42343/42921/4237/18816/19038/37824/36631/36615/1779/17836/443
HYPERTENSIONVascular disorders33/43021/42315/42910/4232/1882/19039/37811/36626/36615/17710/17820/443
ALANINE AMINOTRANSFERASE INCREASEDInvestigations32/43039/42344/42912/4236/1888/19033/37823/36630/36618/1779/17819/443
LATENT TUBERCULOSISInfections and infestations1/4301/4231/4292/4230/1880/19022/3784/36619/36617/1778/1785/443
BRONCHITISInfections and infestations28/43033/42313/42910/4236/1883/19027/37812/36616/36616/1776/17825/443

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean50.0 ± 12.2550.8 ± 12.1851.4 ± 12.0451.6 ± 12.1849.9 ± 12.4150.8 ± 12.22
Age, Customized
Age, Customized(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 65 years1851823623683711468
65 - < 75 years2428615246211
≥ 75 years22610626
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female98113222239236908
Male11399207191187797
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino2937656053244
Not Hispanic or Latino1821753643703701461
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
White1901873753873771516
Black or African American212139
American Indian/Alaska Native112026
Native Hawaiian or other Pacific Islander012014
Asian1621413734149
Multiple2175621
Extent of Psoriasis
Extent of Psoriasis(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 3% BSA108104218215213858
≥ 3% BSA103108211214210846
Missing000101
Current Use of at Least 1 Non-Biologic DMARD
Current Use of at Least 1 Non-Biologic DMARD(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Yes1741733463533451391
No3739837778314
Presence of Dactylitis
Presence of Dactylitis(Participants)Placebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgAdalimumab 40 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Yes6561127136127516
No1461513022932961188
Missing000101

10 further baseline measures are reported on the registry.

08

Study locations

345 sites
  • Rheum Assoc of North Alabama /ID# 163231
    Huntsville, Alabama 35801, United States
  • SunValley Arthritis Center, Lt /ID# 161221
    Peoria, Arizona 85381, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 159981
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 160033
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 160036
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis & Rheuma Research /ID# 160037
    Phoenix, Arizona 85032, United States
  • AZ Arth & Rheum Res /ID# 166381
    Tucson, Arizona 85704, United States
  • Little Rock Diagnostics Clinic /ID# 165161
    Little Rock, Arkansas 72205, United States
  • Covina Arthritis Clinic /ID# 159891
    Covina, California 91722, United States
  • St. Joseph Heritage Healthcare /ID# 159980
    Fullerton, California 92835, United States
  • C.V. Mehta MD, Med Corporation /ID# 161216
    Hemet, California 92543, United States
  • Care Access Research, Huntingt /ID# 160038
    Huntington Beach, California 92648, United States
  • Kotha and Kotha /ID# 159823
    La Mesa, California 91942, United States
  • TriWest Research Associates- La Mesa /ID# 159887
    La Mesa, California 91942, United States
  • Arthritis & Osteo Medical Ctr /ID# 166760
    La Palma, California 90623-1728, United States
  • University of California, Los Angeles /ID# 164542
    Los Angeles, California 90095, United States
  • VA Sacramento Medical Center /ID# 164196
    Mather, California 95655, United States
  • East Bay Rheumatology Medical /ID# 166382
    San Leandro, California 94578, United States
  • Inland Rheum Clin Trials Inc. /ID# 159828
    Upland, California 91786, United States
  • Medvin Clinical Research /ID# 160034
    Whittier, California 90606, United States
  • Denver Arthritis Clinic /ID# 159873
    Denver, Colorado 80230, United States
  • Arthritis and Rheum Clin N. CO /ID# 160039
    Fort Collins, Colorado 80528, United States
  • Colorado Arthritis Associates /ID# 159847
    Lakewood, Colorado 80228, United States
  • Stamford Therapeutics Consorti /ID# 165131
    Stamford, Connecticut 06905, United States
  • Clinical Res of West FL, Inc. /ID# 159829
    Clearwater, Florida 33765, United States
  • International Medical Research - Daytona /ID# 160040
    Daytona Beach, Florida 32117, United States
  • Omega Research Maitland, LLC /ID# 164193
    DeBary, Florida 32713-2260, United States
  • LeJenue Research Associates /ID# 170965
    Miami, Florida 33126, United States
  • Precision Research Org, LLC /ID# 161287
    Miami Lakes, Florida 33016-1501, United States
  • Medallion Clinical Research Institute, LLC /ID# 161228
    Naples, Florida 34102, United States
  • Millennium Research /ID# 159822
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc. /ID# 163465
    Palm Harbor, Florida 34684, United States
  • Gulf Region Clinical Res Inst /ID# 159851
    Pensacola, Florida 32514, United States
  • BayCare Medical Group /ID# 159792
    St. Petersburg, Florida 33705, United States
  • W. Broward Rheum Assoc Inc. /ID# 161388
    Tamarac, Florida 33321, United States
  • Clinical Research of West Florida, Inc /ID# 160063
    Tampa, Florida 33606-1246, United States
  • University of South Florida /ID# 161286
    Tampa, Florida 33612, United States
  • BayCare Medical Group, Inc. /ID# 159879
    Tampa, Florida 33614-7101, United States
  • Florida Medical Clinic /ID# 159992
    Zephyrhills, Florida 33542, United States
  • Institute of Arthritis Researc /ID# 165873
    Idaho Falls, Idaho 83404, United States
  • Advanced Clinical Research /ID# 159894
    Meridian, Idaho 83642, United States
  • Great Lakes Clinical Trials /ID# 163435
    Chicago, Illinois 60640, United States
  • OrthoIllinois /ID# 164546
    Rockford, Illinois 61114-4937, United States
  • Clinical Investigation Specialists - Skokie /ID# 160062
    Skokie, Illinois 60076, United States
  • Deerbrook Medical Associates /ID# 159804
    Vernon Hills, Illinois 60061, United States
  • Graves Gilbert Clinic /ID# 161285
    Bowling Green, Kentucky 42101, United States
  • Four Rivers Clinical Research /ID# 159982
    Paducah, Kentucky 42001, United States
  • Ochsner Clinic Foundation-New Orleans /ID# 165672
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins University /ID# 167665
    Baltimore, Maryland 21224, United States
  • Klein & Associates, M.D., P.A. /ID# 164013
    Cumberland, Maryland 21502, United States
  • The Center for Rheumatology & Bone Research /ID# 159874
    Wheaton, Maryland 20902, United States
  • Tufts Medical Center /ID# 165144
    Boston, Massachusetts 02111, United States
  • Mansfield Health Center /ID# 159805
    Mansfield, Massachusetts 02048, United States
  • Clinical Pharmacology Study Gr /ID# 158700
    Worcester, Massachusetts 01605, United States
  • Univ of Michigan Hospitals /ID# 164014
    Ann Arbor, Michigan 48109, United States
  • Aa Mrc Llc /Id# 159846
    Grand Blanc, Michigan 48439, United States
  • Advanced Rheumatology, PC /ID# 159893
    Lansing, Michigan 48910, United States
  • Beals Institute PC /ID# 163128
    Lansing, Michigan 48917, United States
  • Shores Rheumatology, PC /ID# 159889
    Saint Clair Shores, Michigan 48081, United States
  • St. Luke's Hospital of Duluth /ID# 165671
    Duluth, Minnesota 55805, United States
  • Clinvest Research LLC /ID# 161227
    Springfield, Missouri 65810-2607, United States
  • Clayton Medical Associates dba Saint Louis Rheumatology /ID# 159878
    St Louis, Missouri 63119-3845, United States
  • Glacier View Research Institut /ID# 167023
    Kalispell, Montana 59901, United States
  • Westroads Clinical Research /ID# 159979
    Omaha, Nebraska 68114, United States
  • Dartmouth-Hitchcock Medical Center /ID# 161235
    Lebanon, New Hampshire 03756, United States
  • Arthritis and Osteoporosis Associates /ID# 159802
    Freehold, New Jersey 07728, United States
  • Atlantic Coast Research /ID# 159799
    Toms River, New Jersey 08755, United States
  • Ocean Rheumatology, PA /ID# 163898
    Toms River, New Jersey 08755, United States
  • Arthritis and Osteo Assoc /ID# 159994
    Las Cruces, New Mexico 88011, United States
  • Santa Fe Rheumatology /ID# 163783
    Santa Fe, New Mexico 87505, United States
  • NYU Langone Rheum Assoc /ID# 159985
    Lake Success, New York 11554, United States
  • NYU Langone Medical Center /ID# 163230
    New York, New York 10016-6402, United States
  • St. Lawrence Health System /ID# 159848
    Potsdam, New York 13676, United States
  • American Health Research /ID# 164354
    Charlotte, North Carolina 28207, United States
  • DJL Clinical Research, PLLC /ID# 161390
    Charlotte, North Carolina 28210-8508, United States
  • M3-Emerging Medical Research, LLC /ID# 161391
    Durham, North Carolina 27704, United States
  • Physicians East, PA /ID# 159872
    Greenville, North Carolina 27834, United States
  • Cape Fear Arthritis Care /ID# 161224
    Leland, North Carolina 28451, United States
  • Shanahan Rheuma & Immuno /ID# 159987
    Raleigh, North Carolina 27617, United States
  • Trinity Health Med Arts Clinic /ID# 159800
    Minot, North Dakota 58701, United States
  • MetroHealth Medical Center /ID# 159888
    Cleveland, Ohio 44109, United States
  • The Ohio State University /ID# 159892
    Columbus, Ohio 43210, United States
  • Clinical Research Source, Inc. /ID# 164545
    Perrysburg, Ohio 43551, United States
  • STAT Research, Inc. /ID# 161392
    Vandalia, Ohio 45377-9464, United States
  • Health Research of Oklahoma /ID# 159880
    Oklahoma City, Oklahoma 73103-2400, United States
  • Altoona Ctr Clinical Res /ID# 159852
    Duncansville, Pennsylvania 16635, United States
  • PA Regional Center /ID# 165670
    Wyomissing, Pennsylvania 19610, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 163464
    Summerville, South Carolina 29486-7887, United States
  • West Tennessee Research Inst /ID# 159871
    Jackson, Tennessee 38305, United States
  • Rheumatology Consultants, PLLC /ID# 159796
    Knoxville, Tennessee 37909, United States
  • Dr. Ramesh Gupta /ID# 160061
    Memphis, Tennessee 38119, United States
  • Accurate Clinical Management /ID# 159905
    Baytown, Texas 77521, United States
  • Diagnostic Group Integrated He /ID# 159794
    Beaumont, Texas 77701, United States
  • Arth and Osteo Clin Brazo Valley /ID# 163436
    College Station, Texas 77845, United States
  • PCCR Solution /ID# 205723
    Colleyville, Texas 76034, United States
  • Adriana Pop-Moody MD Clinic PA /ID# 159984
    Corpus Christi, Texas 78404, United States
  • Metroplex Clinical Research /ID# 159785
    Dallas, Texas 75231, United States
  • Rheumatic Disease Clin Res Ctr /ID# 161240
    Houston, Texas 77004, United States
  • Rheumatology Clinic of Houston /ID# 161234
    Houston, Texas 77065, United States
  • "DMCR-Texas Cent for Drug Dev /ID# 164191
    Houston, Texas 77081, United States

Showing the first 100 of 345 sites across 46 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29. PubMed 38683479 ↗
  • Cantini F, Marchesoni A, Novelli L, Gualberti G, Marando F, McDearmon-Blondell EL, Gao T, McGonagle D, Salvarani C. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology (Oxford). 2024 Nov 1;63(11):3146-3154. doi: 10.1093/rheumatology/keae057. PubMed 38331400 ↗
  • Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20. PubMed 37982966 ↗
  • Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PubMed 37945286 ↗
  • Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther. 2023 Apr 10;25(1):56. doi: 10.1186/s13075-023-03027-5. PubMed 37038159 ↗
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. PubMed 36754548 ↗
  • McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Haaland D, Chen L, Duan Y, Liu J, Lippe R, Wung P. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatol Ther. 2023 Feb;10(1):275-292. doi: 10.1007/s40744-022-00499-w. Epub 2022 Oct 15. PubMed 36243812 ↗
  • Mease P, Kavanaugh A, Gladman D, FitzGerald O, Soriano ER, Nash P, Feng D, Lertratanakul A, Douglas K, Lippe R, Gossec L. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatol Ther. 2022 Aug;9(4):1181-1191. doi: 10.1007/s40744-022-00449-6. Epub 2022 May 23. PubMed 35606663 ↗
  • Burmester GR, Winthrop K, Blanco R, Nash P, Goupille P, Azevedo VF, Salvarani C, Rubbert-Roth A, Lesser E, Lippe R, Lertratanakul A, Mccaskill RM, Liu J, Ruderman EM. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther. 2022 Apr;9(2):521-539. doi: 10.1007/s40744-021-00410-z. Epub 2021 Dec 30. PubMed 34970731 ↗
  • Nash P, Richette P, Gossec L, Marchesoni A, Ritchlin C, Kato K, McDearmon-Blondell EL, Lesser E, McCaskill R, Feng D, Anderson JK, Ruderman EM. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8):3257-3268. doi: 10.1093/rheumatology/keab905. PubMed 34864911 ↗
  • Strand V, Mease PJ, Soriano ER, Kishimoto M, Salvarani C, Saffore CD, Zueger P, McDearmon-Blondell E, Kato K, Gladman DD. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Rheumatol Ther. 2021 Dec;8(4):1789-1808. doi: 10.1007/s40744-021-00379-9. Epub 2021 Oct 12. PubMed 34636026 ↗
  • Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022 Jan;15(1):267-278. doi: 10.1111/cts.13146. Epub 2021 Oct 27. PubMed 34464029 ↗
  • McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, Zueger P, Liu J, Pangan AL, Behrens F. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227-1239. doi: 10.1056/NEJMoa2022516. PubMed 33789011 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Sep 2019, 28 months.

Results were first posted in Jan 2022, 2 years 3 months after primary completion. A results delay was requested in Aug 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 28 months is close to that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 7, 2017
StartActual
Apr 27, 2017
Primary completionActual
Sep 26, 2019
CompletionActual
Sep 9, 2024
Results delay requested
Aug 18, 2020
Results first posted
Jan 25, 2022
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03104400
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Apr 27, 2017
Primary completion
Sep 26, 2019
Completion
Sep 9, 2024
Results posted
Jan 25, 2022
Last update
Sep 22, 2025

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion